Vocalbeats.AI Achieves ISO/IEC 42001 Certification, Reinforcing Responsible AI Governance ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development
YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage…
ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development
YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage…
Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) — Cerevance, a private, clinical-stage drug discovery and development…
Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) — Cerevance, a private, clinical-stage drug discovery and development…
Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software
Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines PRINCETON, N.J., Sept….
Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software
Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines PRINCETON, N.J., Sept….
Panbela to Present at the LD Micro Investor Conference
MINNEAPOLIS, Sept. 19, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company…
Panbela to Present at the LD Micro Investor Conference
MINNEAPOLIS, Sept. 19, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company…
IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents
Newly granted patents expand the use of the DeltEx Drug Resistant Immunotherapy (DRI) platform to…
IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents
Newly granted patents expand the use of the DeltEx Drug Resistant Immunotherapy (DRI) platform to…
Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs
Event on October 19, 2023 will feature Sonata Jodele, MD and Professor Rob Wynn BOSTON…
Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs
Event on October 19, 2023 will feature Sonata Jodele, MD and Professor Rob Wynn BOSTON…
Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023
SEATTLE, Sept. 19, 2023 (GLOBE NEWSWIRE) — Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging…
Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023
SEATTLE, Sept. 19, 2023 (GLOBE NEWSWIRE) — Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging…
BioVie to Participate in the Cantor Fitzgerald Global Healthcare Conference
CARSON CITY, Nev., Sept. 19, 2023 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (“BioVie” or…
BioVie to Participate in the Cantor Fitzgerald Global Healthcare Conference
CARSON CITY, Nev., Sept. 19, 2023 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (“BioVie” or…
Akoya Biosciences Sets a New Standard for Scaling Spatial Biology with the Launch of 2.0 Platforms
PhenoCycler-Fusion 2.0 enhancements enable the highest throughput workflow for spatial discovery studies. PhenoImager HT 2.0…
Akoya Biosciences Sets a New Standard for Scaling Spatial Biology with the Launch of 2.0 Platforms
PhenoCycler-Fusion 2.0 enhancements enable the highest throughput workflow for spatial discovery studies. PhenoImager HT 2.0…